Medtronic Care - HF

 

Medtronic

Indications, contraindications, warnings, precautions, and adverse events

Privacy Statement
Terms of Use

CArdiac REsynchronization in Heart Failure

Preliminary results presented at the American College of Cardiology 2005 Conference; Article published in the April 2005 issue of The New England Journal of Medicine.

The CARE-HF clinical trial analyzed the effects of cardiac resynchronization therapy (CRT) on morbidity and mortality in patients who were receiving optimal medical therapy for moderate or severe heart failure due to left ventricular systolic dysfunction (LVSD) and cardiac dyssynchrony.

Care-HF: Request a copy of the New England Journal of Medicine article.

Conclusion:

The study showed that CRT should be routinely considered as an adjunct to optimal medical therapy for patients with moderate to severe heart failure due to left ventricular systolic dysfunction (LVSD) and cardiac dyssynchrony because it

  • Reduced risk of all-cause mortality
  • Reduced risk of all-cause mortality or unplanned cardiovascular hospitalization
  • Reduced risk of all-cause mortality or unplanned heart failure hospitalization

These benefits are in addition to previously established outcomes of CRT, including improved cardiac structure and function, symptoms, and quality of life (QoL).5,7-13

Results:

Primary endpoint: all-cause mortality or unplanned cardiovascular hospitalization

Secondary endpoint: all-cause mortality